Biocytogen Pharmaceuticals Beijing (2315) H1 2025 earnings summary

Executive summary

• H1 revenue rose 51.3% YoY to RMB621.0m; net profit was RMB48.0m, versus a RMB50.7m loss in H1 2024.

• Operating cash flow reached RMB203.4m and net cash flow turned positive at RMB33.3m.

Financial highlights

• Gross profit rose 51.2% to RMB461.9m; operating profit was RMB107.4m versus RMB14.7m in H1 2024.

• Basic EPS was RMB0.12, versus a loss per share of RMB0.13 in H1 2024.

• R&D expenses increased 29.3% to RMB209.1m; selling and marketing expenses rose 37.6% to RMB58.5m.

• G&A expenses rose 13.3% to RMB116.2m, primarily due to higher staff costs, bonuses and share-based payments.

Outlook and guidance

• FY2025 aim: progress toward large-scale profitability while sustaining R&D investment, controlling expenses and improving operating efficiency.

• Priorities include expanding RenMice and Project Integrum, advancing preclinical PCC molecules for partner licensing, and broadening animal models and global operations.

• AI tools integrated with Project Integrum are being developed to improve antibody discovery and partner R&D efficiency.